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The EORTC Leukemia Group (LG) has a long history of promoting the study of
leukemias and related malignancies and reports here on three of their most
signiﬁcant achievements. In acute myelogenous leukemia (AML), the LG and Italian
group GIMEMA started their fruitful collaboration in 1986 with the AML-8 trial with
1519 inclusions. In the AML-8A trial, in patients who reached complete remission,
without a HLA identical sibling, autograft provided longer disease-free survival than
a second course of consolidation, whereas the best outcome was observed in patients
with a donor, who had to be allografted. The AML-10 trial set a new standard of
treatment for induction/consolidation with replacement of daunorubicin by either
idarubicin or mitoxantrone. The AML-12 trial tested the effect of high-dose cytosine-
arabinoside during induction (2109 inclusions, data base locked in August 2011
for ﬁnal analysis). Development of intergroup trials focusing on subgroups of AML
bearing speciﬁc genetic abnormalities is now mandatory to validate the “targeted
approach” of driving molecular events. In high-risk myelodysplastic syndrome (MDS),
the phase III trial conducted by the LG in collaboration with the German MDS Study
Group showed that the response rate of decitabine versus best supportive care was
higher (complete or partial remissions, 19% versus 0%, and hematologic improvement,
15% versus 2%), progression-free survival was signiﬁcantly prolonged (median
6.6 versus 3 months), cumulative incidence of AML was signiﬁcantly decreased
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(22% versus 33% at one year), but the impact on OS was less evident (median
10.1 versus 8.5 months; hazard ratio 0.88). Quality of life had improved signiﬁcantly
in patients in the decitabine arm. The assessment of HDAC inhibitors, such as
vorinostat, will probably be tested in the next trial. Also in MDS, relevant genetic
lesions involved in the pathogenesis of this disease were identiﬁed using single
nucleotide polymorphisms array-based genomic proﬁling and genomic sequencing
in 102 patients with MDS. Acquired abnormalities of the TET2 gene were identiﬁed
in 26% of the cases and in the EZH2 gene in 5−10% of the patients. TET2 mutations
were detected in 96% of the bone marrow cells, including CD34+ progenitor cells,
suggesting that TET2 mutations could be an early event during disease evolution.
In normal bone marrow, TET2 expression was elevated in granulocytes, suggesting a
role in myelopoiesis.
Conclusion: during the last 25 years the EORTC LG in cooperation with GIMEMAmade
a considerable contribution to the improvement of treatment results of patients with
acute leukemia or MDS.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The aim of the EORTC Leukemia Group (LG) is to
promote the study of leukemias and related malig-
nancies with regard to their natural history, diagnosis,
treatment and sequelae of treatment. Speciﬁcally, the
LG organizes phase I, II and III trials for patients with
myeloid or lymphoid leukemias and myelodysplastic
syndromes (MDS).
2. Optimizing treatment in acute myelogenous
leukemia
The treatment of acute myelogenous leukemia (AML)
relies on two active drugs used in this disease dating back
40 years: daunorubicin, an anthracycline, being a DNA
intercalating agent, associated with cytosine arabinoside,
an antimetabolite, for induction treatment, followed
by the same association using cytosine arabinoside at
higher dose (consolidation). According to cytogenetic
and molecular biology, intensiﬁcation could be allograft,
autograft, or courses of high doses of cytosine arabi-
noside. With the induction treatment, approximately
60% to 80% of adults with AML achieve complete
remission (CR). Strategies to improve anti-tumor efﬁcacy
have included the addition of a third drug (etoposide) and
the substitution of daunorubicin by other anthracyclines:
idarubicin or mitoxantrone. However, because of the
relatively small sample size and/or the relatively short
follow-up time, the beneﬁts of these new agents on the
long-term outcome of patients with AML have not been
deﬁnitively established.
The aim of the EORTC LG and GIMEMA AML-10
trial was to compare the efﬁcacy and toxicity of
three different anthracyclines in combination with
cytarabine and etoposide in adult patients with newly
diagnosed AML. This study randomly assigned 2,157
patients (age range 15 to 60 years) to receive intensive
induction–consolidation chemotherapy containing either
daunorubicin, or idarubicin, or mitoxantrone. After
achieving CR, patients were assigned to undergo either
allogenic or autologous stem-cell transplantation (SCT)
depending on the availability of a sibling donor. The
overall CR rate (69%) was similar in the three groups.
The proportion of patients who underwent allogenic SCT
was equivalent in the three treatment groups, and the
outcome was similar as well. The 5-year overall survival
rates were 34%, 34%, and 31%, respectively. In patients
who reached CR and did not have a donor, autologous
SCT was performed in 41%, 47% and 54% of patients
in the mitoxantrone, idarubicin and daunorubicin arms,
respectively. However, the disease-free survival (DFS)
and survival from CR were signiﬁcantly longer in
the mitoxantrone and idarubicin arms than in the
daunorubicin arm: the 5-year DFS rates were 37%, 37%,
and 29%, respectively. So, in adult patients with AML who
should not receive allogenic stem cell transplantation,
the long-term efﬁcacy of chemotherapy is enhanced
through the use of mitoxantrone or idarubicin instead
of daunorubicin. 1
This trial set a new standard of treatment for
induction/consolidation in AML, with replacement of
daunorubicin by either idarubicin or mitoxantrone.
This fruitful collaboration between the LG and GIMEMA
began in 1986 with the AML-8 trial, with 1519 inclusions.
In the AML-8A trial (testing autograft in ﬁrst CR) in
patients45 years old, who reached complete remission,
in those without a HLA donor, autograft provided
longer disease-free survival than a second course of
consolidation, whereas the best outcome was observed
in patients with an HLA identical sibling, who had
to be allografted. 2 In the last EORTC–GIMEMA AML-12
study, efﬁcacy and toxicity of high dose vs standard
dose of cytosine–arabinoside during induction and of
IL-2 post-consolidation/autologous SCT were tested (2109
inclusions, data base was locked in August 2011 for ﬁnal
analysis).
Open access under CC BY-NC-ND license.
96 ejc supplements 10, no. 1 (2012) 94–98
With the development of molecular diagnosis per-
mitting targeted therapy (for example ﬂt3 duplica-
tion/mutation), the era of large multicenter trials is
probably over for AML. Intergroup trials now take on
even more importance due to the small number of AML
patients with particular molecular abnormality able to be
enrolled by each group. One of the ﬁrst examples is the
CALGB/EORTC 06071 midostaurin trial in patients with
ﬂt3 duplication/mutation.
3. Optimizing treatment in myelodysplastic
syndrome
Medical management of MDS remains challenging. Over
the past decade, epigenetic changes such as alterations
in DNA methylation and histone modiﬁcations have
been well described in MDS and are now recognized
as therapeutic targets (epigenetic therapy). Since epige-
netic silencing is reversible by pharmacological means,
treatment approaches to target the aberrant epigenome
of malignant cells have been developed. Building
on encouraging phase II data with low-dose 5-aza-
2′deoxycytidine (decitabine, Dacogen) which resulted in
a ~50% overall response rate in mostly higher-risk MDS
patients, even in the presence of poor risk cytogenetics
including complex karyotypes, 3−5 the EORTC LG together
with the German MDS Study Group conducted a phase III
trial investigating the efﬁcacy and toxicity of decitabine
given intravenously over three days, repeated every six
weeks. 6
The control arm chosen for this trial was best
supportive care (BSC), without the option of a “cross-
over”. The patient population was deﬁned by higher-
risk features such as blast cells excess of 11−30% in the
bone marrow, and/or adverse cytogenetic abnormalities.
To be registered for this trial of non-intensive treatment,
patients were to be deemed ineligible for intensive
chemotherapy by the treating physician. Between Oc-
tober 2002 and May 2007, 233 patients from 40 centers
in nine European countries were randomized. According
to the IPSS international score, 92% of patients had
“higher-risk” disease and 32% fulﬁlled the WHO criteria
of AML, i.e., at least 20% blasts. Notably, 53% of patients
with known cytogenetic had poor-risk karyotypes. The
median duration of MDS at randomization was only
three months. The median number of decitabine courses
administered was four, i.e., approximately six months
of treatment. Median time for patients to exit from
the study was 5.9 months in the decitabine arm versus
3.7 months in the BSC arm (P< 0.001).
Overall survival (OS), the primary end point of the
study, was 10.1 months (median) in the decitabine arm
versus 8.5 months in the BSC arm (HR=0.88; 95%CI:
0.66−1.17) and did not reach statistical signiﬁcance.
Progression-free survival (PFS) was signiﬁcantly pro-
longed in patients receiving decitabine (P = 0.004), more
than doubling of the median PFS (from 3 to 6.6 months)
and a reduction of the hazard rate of 32% (HR=0.68;
95%CI: 0.52−0.88). The cumulative incidence of AML
was signiﬁcantly decreased with decitabine treatment
compared to BSC (22% versus 33% at one year, 30% versus
43% at two years), with similar cumulative incidences
of death without AML in both arms. There were 19%
complete or partial remissions in the decitabine arm
versus 0% in the BSC arm; hematologic improvement:
15% versus 2%. By multivariate analyses, IPSS high-
risk, poor cytogenetic, <3 months of MDS duration and
performance status ECOG 1 or 2 were independent
prognostic factors for OS, PFS, and AML-free survival.
Grade 3 to 4 infections were the most frequent
adverse events in both arms. Quality of life was
signiﬁcantly improved in patients on the decitabine arm
(self-reported fatigue and physical functioning), with
borderline improvement of global health status. For most
other quality of life scales, the trend was also in favor of
decitabine.
This phase III trial of decitabine versus best supportive
care in older, medically non-ﬁt MDS patients with
higher-risk MDS conﬁrms, at a large scale, the efﬁcacy
of the drug in this patient population. 7 Response
rates were in line with previous trials with this drug
performed previously by the principal investigators of
this trial 3−5: a signiﬁcant prolongation of PFS and a
reduction in the AML transformation rate. The lack of
signiﬁcant prolongation of OS may be due in part to
the high proportion of patients with rapidly evolving
high-risk MDS (AML?) having been recruited on this
study. Further studies with decitabine are warranted
in this patient population, e.g. comparison with the
4-week decitabine schedule, combinations with histone
deacetylase inhibitors, and maintenance treatment with
even lower-dose schedules.
4. Translational research: TET2 in MDS and AML
Until now the genes affected in MDS have remained
largely unknown, despite the numerous chromosomal
aberrations described in MDS.To identify relevant genetic
lesions involved in the pathogenesis of MDS, J. Jansen
and his colleagues in the EORTC NOCI (Network of Core
Institutions) center of Nijmegen conducted SNP array-
based genomic proﬁling and genomic sequencing in 102
patients with MDS and identiﬁed acquired abnormalities
of the TET2 gene (deletions, missense or nonsense
mutations) in 26% of the cases 8 and in EZH2 in 5−10% of
the patients. 9 TET2 mutations were detected in most of
the bone marrow cells (96%), including CD34+ progenitor
cells, suggesting that TET2 mutations could be an early
event during disease evolution. In normal bone marrow,
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TET2 expression was elevated in granulocytes, suggesting
a role in myelopoiesis. Until now, TET2 is the most
frequently mutated gene in MDS.
The role of TET genes begins to unfold: the family
of the three TET (TET1, TET2, TET3) proteins share
two conserved regions that may be implicated in
DNA epigenetic modiﬁcation, 10 and these regions are
implicated in a novel form of DNA modiﬁcation: con-
version of 5-methylcytosine to 5-hydroxymethylcytosine.
TET expression might lead to demethylation of DNA and
de-repression of gene expression, and on the other hand
TET mutation might lead to DNA hypermethylation and
repression of tumor suppressor genes.
Translational research performed by the LG focused
also on the prognostic impact of mutations and correla-
tion with known genetic defects of this novel oncogene/
tumor suppressor in de novo acute myeloid leukemia
patients treated in the AML-12 trial (phase III EORTC
trial 06991). This project, presented by S. Langemeijer
and J. Jansen PhD, was granted by the EORTC in 2009
and results will be available soon from samples from
four main EORTC centers and several GIMEMA centers.
In MDS, our aim is to investigate the clinical response to
demethylating agents in TET2 mutated versus TET2 wild-
type MDS patients as well as in MDS with high versus low
TET2 expression (non-mutated).
5. Strategy for the coming years
The molecular events driving the development of
leukemia and myelodysplasia (core binding factors
translocation, ﬂt-3 mutation, TET2 mutation, nucle-
ophosmin mutation, etc.) are now systematically an-
alyzed at diagnosis in AML and MDS, and some of
these molecular markers are also used for monitoring
residual disease in blood and bone marrow. According
to the level of mutated allele, or to the presence of
mutated oncogenes, the treatment of AML/MDS will
be adapted. Now it is possible to get the results of
the major mutation/translocation events within three
working days which allows the inclusion of de novo
untreated AML in randomized trials to test the efﬁcacy
of speciﬁc inhibitors, such as the ﬁrst generation anti-
ﬂt3 inhibitor midostaurin associated with “classical”
chemotherapy (trial CALGB/EORTC 06071) [ﬂt3 mutation
status performed in the NOCI center of Nijmegen
(J. Jansen)]. The era of large trials including more than
2000 AML patients (such as EORTC trials AML-12 and
AML-10) is now ﬁnished, but development of intergroup
trials focusing on subgroups of AML bearing speciﬁc
genetic abnormalities is now mandatory to validate the
“targeted approach” of drivingmolecular events. Addition
of promising drug in AML like clofarabine to standard
chemotherapy is currently tested in a phase II trial in
EORTC and GIMEMA centers (AML14A, 06061).
The treatment of elderly AML, where complex kary-
otypes are more frequent, is a challenge for the LG.
As have others, we noted the absence of improvement
in OS (<10% at 5 years) for patients included in our
subsequent elderly AML trials. For elderly patients with
AML, unﬁt for intensive chemotherapy, our EORTC–
GIMEMA trial (AML-19) is currently testing the use of
very low dose of gemtuzumab ozogamycin to improve
quality of life and overall survival. We are planning
to build a platform for patients over 55 years of age,
including systematic tumor cell banking at diagnosis, a
standard 3+7 treatment (versus experimental “pick the
winner” arm), followed by reduced intensity conditioning
regimen (RIC) allograft in patient in remission, provided
performance status is adequate, and there are available
donors. The adoptive immunotherapy of this allograft
represents a very interesting option in these patients,
who have a very high rate of relapse within one year.
Concerning high-risk MDS, the next step will be the
improvement of the results obtained with demethylating
agents (decitabine and 5-azacytidine). The duration of
hematological responses with demethylating agents is
limited, and promising preliminary results were obtained
when these agents are used in combination with HDAC
inhibitors, such as vorinostat. 11
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